title: Familial Pancreatic Adenocarcinoma.
abstract: Familial pancreatic cancer (FPC) kindreds have at least 2 first-degree relatives with pancreatic ductal adenocarcinoma. Studies of FPC have focused on the discovery of genetic cause and on the management of those at genetically high risk. Research reveals that a half dozen known hereditary syndromes or genes are associated with increased risk of developing pancreatic cancer, the most prominent of which are BRCA2 and CDKN2A. Genetic risk assessment and testing is already available. Owing to limited experience worldwide, guidance is often based on expert opinion, although all agree that research is needed to improve the shaping of options.
authors.affiliation: Department of Health Sciences Research, Mayo Clinic Cancer Center, Mayo Clinic, Charlton 6-243, Rochester, MN 55905, USA. Electronic address: Petersen.gloria@mayo.edu.
authors.forename: Gloria M
authors.initials: GM
authors.lastname: Petersen
mesh_terms: D000230:Adenocarcinoma / Q000453:epidemiology / Q000235:genetics* / Q000628:therapy; D002277:Carcinoma / Q000453:epidemiology / Q000235:genetics* / Q000628:therapy; D020022:Genetic Predisposition to Disease; D005820:Genetic Testing; D018095:Germ-Line Mutation; D006801:Humans; D010190:Pancreatic Neoplasms / Q000453:epidemiology / Q000235:genetics* / Q000628:therapy; D057285:Precision Medicine; D012307:Risk Factors
keywords: Familial risk; Genetic susceptibility; Genetic testing; Risk assessment and management